PYPD (PolyPid) Institutional Ownership : 24.98% (As of Jun. 24, 2025)

View and export this data going back to 2020. Start your Free Trial

What is PolyPid Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, PolyPid's institutional ownership is 24.98%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, PolyPid's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, PolyPid's Float Percentage Of Total Shares Outstanding is 69.21%.

PolyPid Institutional Ownership Historical Data

The historical data trend for PolyPid's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PolyPid Institutional Ownership Chart

PolyPid Historical Data

The historical data trend for PolyPid can be seen below:

	2024-08-31	2024-09-30	2024-10-31	2024-11-30	2024-12-31	2025-01-31	2025-02-28	2025-03-31	2025-04-30	2025-05-31
Institutional Ownership	0.19	0.19	0.18	0.18	0.12	0.12	0.12	0.12	0.12	0.12

PolyPid Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

PolyPid Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PolyPid Ltd (NAS:PYPD) » Definitions » Institutional Ownership

Comparable Companies

Traded in Other Exchanges

N/A

Address

18 Hasivim Street, P.O Box 7126, Petach Tikva, ISR, 495376

Website

https://www.polypid.com

PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. Its product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.